Pure Global AI
NCT06294561Recruiting

TGRX-326 Pharmacokinetic Drug Interaction

An Open-label, Two-cycle, Single Sequence, Self-controlled Study Evaluating Effects of Oral Itraconazole or Efavirenz on Pharmacokinetic Profiles of TGRX-326
Shenzhen TargetRx, Inc.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non Small Cell Lung Cancer
Drug/Device/Intervention
Itraconazole+TGRX-326
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Shenzhen TargetRx, Inc.
Location
Nanjing, China
Timeline & enrollment
Phase
Phase 1
Start date
Mar 04, 2024
End date
Jun 30, 2024
Enrollment
32 participants
Primary outcome

Plasma Tmax,Plasma Cmax,Plasma AUC(0-t),Plasma AUC(0-inf),T1/2,Plasma volume of distribution (Vz/F),Plasma clearance (CL/F)

Summary

This is a drug-drug interaction study for TGRX-326 to evaluate the effects of CYP3A
 inhibitor/inducer drugs on pharmacokinetic profiles of TGRX-326, an ALK inhibitor indicated
 for treatment of Non-small cell lung cancer.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06294561
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06294561 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shenzhen TargetRx, Inc. and is currently Recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.